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Epidemiology of premature vascular damage in 
systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is an autoimmune 
disease with heterogeneous manifestations, including 
internal organ damage, which can result in severe 
morbidity and even death and often requires aggressive 
immunosuppressive treatment. More than 30 years ago, a 
bimodal peak in mortality was described in lupus patients, 
with late increases in death commonly seen as secondary 
to premature cardiovascular disease (CVD) [1]. Indeed, 
this enhanced atherosclerotic risk increases with each year 
of disease duration. Th  is is especially the case in young 
females with SLE, where the CVD risk can be up to 50-fold 
higher than in age-matched controls [2,3]. While 
traditional Framingham risk factors likely contri  bute to 
CVD in SLE, they cannot fully account for the increased 
risk. Instead, the pathogenesis of premature CVD in SLE 
may rely on factors unique to the disease itself [4].
While systemic inﬂ   ammation has been linked to 
atherosclerosis development in the general population 
and in speciﬁ   c conditions, SLE typically has a lower 
‘classical inﬂ  ammatory burden’ compared to what would 
be seen in rheumatoid arthritis or spondylo  arthro-
pathies; yet, lupus is associated with a higher CVD risk 
than these other diseases. Th  is observation suggests 
that factors that trigger accelerated atherosclerosis in 
lupus diﬀ  er from the typical proinﬂ  ammatory factors 
(that is, high C-reactive protein (CRP)) linked to 
‘idiopathic’ athero  sclerosis. Atherosclerosis progression 
in lupus patients develops or progresses in 10% of SLE 
patients per year. Among other factors, this progression 
is associated with older age at diagnosis and with longer 
disease duration, supporting the hypothesis that chronic 
exposure to lupus immune dysregulation promotes 
CVD [5].
Subclinical and clinical vascular damage in SLE
Premature damage in SLE occurs in both the macro- and 
microvasculature. Vascular functional abnormalities in 
lupus are present even shortly after disease diagnosis [6]. 
SLE patients have signiﬁ  cantly decreased ﬂ  ow-mediated 
dilation of the brachial artery and this correlates with 
increased carotid intima media thickness (IMT) [7]. 
Additionally, carotid plaque can be detected in 21% of 
SLE patients under the age of 35 years and in up to 100% 
of those over the age of 65 years [8]. Aortic atherosclerosis 
is also increased in SLE [9]. Th   ese macrovascular ﬁ  ndings 
correlate with disease activity and disease duration [7-9]. 
Damage to the coronary circulation is also common in 
SLE patients, with 54% displaying non-calciﬁ  ed coronary 
plaque [10]. Th   ere is also impairment of coronary micro-
vasculature ﬂ  ow reserve, even in patients with grossly 
normal coronary arteries. Th  is dysfunction correlates 
with disease duration and severity, suggesting that micro-
vascular damage and dysfunction are also part of SLE-
related CV pathology [11]. Additionally, SLE patients 
have a higher probability of developing left ventricular 
hyper  trophy, independent of baseline hypertension, again 
empha  siz  ing the role of lupus-related factors in CVD 
damage [12].
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general population
Various groups have proposed that CVD, endothelial 
dysfunction and atherosclerosis arise from chronic injury 
to the endothelium, which allows for invasion of 
inﬂ  ammatory cells and lipid deposition. Current dogma 
upholds that chronic inﬂ  ammation instigates and per-
petu  ates the atherogenic cycle. Factors such as oxidized 
low density lipoprotein (LDL) activate the endothelium 
to secrete chemokines, which recruit inﬂ  ammatory cells, 
including T lymphocytes, dendritic cells (DCs) and mono-
cytes. Th  ese monocytes diﬀ   erentiate into macro  phages 
and foam cells under the inﬂ   uence of locally secreted 
factors [13]. Various stimuli, including cholesterol crystals, 
then activate macrophages and foam cells to secrete 
inﬂ   ammatory cytokines, reactive oxygen and nitrogen 
species and proteases, all of which contribute to the 
atherogenic phenotype in the blood vessel [14]. Invasion 
of the atherosclerotic plaque by CD4+ T cells also 
contributes to vascular pathology by recognizing epi-
topes of various molecules, including oxidized LDL, and 
by secreting IFN-γ, which then leads to increased 
inﬂ  ammatory cytokine production. Th   is chronic produc-
tion of inﬂ  ammatory cytokines and proteases may lead to 
thinning of the plaque wall and eventual rupture, which 
results in exposure of the blood to phospholipids, tissue 
factor and platelet-adhesive matrix molecules, eventually 
promoting thrombosis and acute CVD events [13].
Coupled to this inﬂ  ammatory injury, a loss of endo  thelial 
cells can occur, which, if not repaired, leads to increased 
inﬂ   ammatory cell invasion, vascular smooth muscle 
proliferation and neo-intima formation [15]. Endo  thelial 
cell apoptosis is a phenomenon with poten  tially signiﬁ  cant 
deleterious eﬀ  ects on vascular health, including loss of 
nitric oxide, generation of phosphatidyl  serine-rich 
microparticles with signiﬁ  cant tissue factor activity, and 
potential predisposition to acute coronary events [16,17].
Under normal conditions, vascular damage triggers a 
response leading to an attempt to repair the endothelium. 
Although our understanding of vascular repair is rapidly 
evolving, it is still unclear how it occurs. Several groups 
have proposed that repair of the vasculature occurs 
primarily by bone marrow-derived endothelial progenitor 
cells (EPCs) and myelomonocytic circulating angiogenic 
cells (CACs) [18]. Indeed, decreased numbers or dys-
function of these cell types may contribute to CVD as 
EPC numbers inversely correlate with CVD risk, time to 
ﬁ   rst CVD event, and in-stent restenosis risk [19,20]. 
Additionally, functional impairment of EPCs correlates 
with coronary artery disease risk [21]. Various mecha-
nisms have been implicated in EPC/CAC dysfunction in 
these conditions, including reactive oxygen species, 
telomere shortening/senescence and cytokines such as 
TNF [22-24].
Mechanisms of endothelial injury and 
atherosclerosis in SLE
Induction of an imbalance of vascular damage and repair 
by type I IFNs
Patients with SLE have increased numbers of circulating 
apoptotic endothelial cells, which correlates with endo-
thelial dysfunction and generation of tissue factor [6]. 
Various soluble adhesion molecules, such as vascular cell 
adhesion molecule (VCAM), inter-cellular adhesion 
molecule and E-selectin, which are released after endo-
thelial cell damage, are increased in SLE and correlate 
with increased coronary calcium scores. Additionally, 
soluble levels of the antithrombotic endothelial protein C 
receptor, which is released secondary to inﬂ  ammatory 
activa  tion of metalloproteinases, are increased in SLE 
and correlate with the presence of carotid plaque [25]. 
Th  ese ﬁ  ndings suggest that chronic vascular insult and 
inﬂ   ammation may be important for atherosclerotic 
pathology [26]. Despite evidence that accelerated endo-
thelial cell death occurs in lupus, a phenomenon that 
should trigger enhanced vascular repair, the latter is 
signi ﬁ   cantly impaired in lupus patients. SLE patients 
have decreased circulating EPCs/CACs, and those that 
persist are characterized by increased apoptosis, even 
during quiescent disease, decreased proangiogenic 
molecule synthesis, and decreased capacity to incor-
porate into formed vascular structures and diﬀ  erentiate 
into mature endothelial cells [27,28] (Figure  1). Th  us, 
patients with SLE have compromised repair of the 
damaged endothelium, likely leading to the establishment 
of a milieu that promotes the development of plaque.
Our group has proposed that the mechanism by which 
vascular repair is impaired in SLE is through increased 
levels and enhanced eﬀ  ects of type I IFNs. Human and 
murine studies from various groups indicate that IFN-α 
may be crucial in the pathogenesis of SLE. SLE patients 
have an ‘IFN signature’ in peripheral blood mononuclear 
cells, kidneys and other tissues that correlates with 
disease activity [29], and type I IFN levels are increased 
in lupus serum [30]. Further, lupus cells appear to be 
more sensitive to the eﬀ  ects of type I IFN [31]. As part of 
this pathology, we and others have suggested that the 
development of lupus-related CVD is, at least partially, 
attributable to IFN-α and, potentially, to other type I 
IFNs. Our group has reported that dysfunction of EPC/
CAC diﬀ   erentiation in SLE is mediated by IFN-α, as 
neutralization of this cytokine restores a normal EPC/
CAC phenotype [28]. Th  is is further reinforced by the 
observation of abrogated EPC/CAC numbers and 
function observed in lupus-prone New Zealand black/
New Zealand white F1 mice, a strain that depends on type 
I IFNs for disease development. Additionally, non-lupus-
prone mice EPCs are unable to properly diﬀ  erentiate into 
mature endothelial cells in the presence of IFN-α [32,33]. 
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repair may depend on repression of the proangiogenic 
factors IL-1β and vascular endothelial growth factor and 
on upregulation of the antiangiogenic IL-1 receptor 
antagonist. Indeed, addition of recombinant human IL-β 
to SLE EPC/CAC cultures restores normal endothelial 
diﬀ  erentiation [32]. Further supporting a role for type I 
IFNs in premature vascular damage in SLE, patients with 
high type I IFN signatures have decreased endothelial 
function, as assessed by peripheral arterial tone measure-
ments [34]. Preliminary evidence indicates that type I 
IFN signatures correlate with carotid IMT in a lupus 
cohort [35]. Furthermore, there is evidence that an anti-
angiogenic phenotype is present in patients with SLE, 
manifested by decreased vascular density and increased 
vascular rarefaction in renal blood vessels in vivo, 
associated with upregulation of the IL-1 receptor antago-
nist and decreased vascular endothelial growth factor in 
both the kidney and serum [28,36].
Th   e cellular source of type I IFNs leading to abnormal 
vascular repair was recently examined. Depletion of 
plasma  cytoid DCs (the major producers of IFN-α) does 
not lead to abrogation of abnormal lupus EPC/CAC 
diﬀ  erentiation in culture [37]; therefore, other cellular 
sources for this cytokine have been sought. Neutrophil-
speciﬁ  c genes are abundant in peripheral blood mono-
nuclear cell microarrays from lupus patients because of 
the presence of low-density granulocytes (LDGs) in 
mononuclear cell fractions [38,39]. Th   e functionality and 
pathogenicity of these LDGs was recently investigated by 
our group. Among other ﬁ  ndings, these cells are signi-
ﬁ  cantly cytotoxic to endothelial cells. In addition, LDGs 
have the capacity to secrete suﬃ   cient amounts of IFN-α 
to interfere with vascular repair. LDG depletion from 
lupus peripheral blood mononuclear cells restores the 
ability of EPC/CACs to diﬀ  erentiate in vitro into endo-
thelial monolayers [37]. Th   is suggests that the presence of 
these abnormal granulocytes contributes to endothelial 
dys  function and vascular damage in SLE.
Th  e above ﬁ   ndings suggest that abrogation of the 
aberrant eﬀ   ects of type I IFNs in SLE may not only 
decrease disease activity but also lead to decreases in CVD 
risk. Future clinical trials should assess this possibility.
Th  e potentially deleterious eﬀ   ects of type I IFNs in 
cardiovascular health are also being explored in non-
SLE-related atherosclerosis. For example, IFN-α-produc-
ing plasmacytoid DCs have been identiﬁ  ed in areas of 
athero  matous plaque. IFN-α then activates plaque-
residing CD4+ T cells to increase TNF-related apoptosis-
inducing ligand (TRAIL) expression, which results in 
killing of plaque stabilizing cells and a potential increase 
in the risk of plaque rupture. Additionally, IFN-α sensi-
tizes plaque-residing myeloid DCs, which may result in 
further inﬂ   ammation and plaque destabilization. Th  is 
cytokine appears to synergize with bacterial products 
(such as lipo  polysaccharide) to increase the synthesis of 
various proinﬂ  ammatory cyto  kines and metallo  protein-
ases [40,41]. Th  ese ﬁ   ndings indicate that type I IFNs 
could potentially be involved in athero  sclerosis develop-
ment not only in autoimmune disorders but also in the 
general population in the context of microbial infections. 
Th   is hypothesis merits further investi  gation. Additionally, 
type I IFNs inhibit CRP up  regulation [42], which may 
explain why the CRP response is usually downregulated 
in SLE ﬂ  ares and why it does not appear to correlate well 
with atherosclerotic burden in this disease [43].
Figure 1. Endothelial progenitor cells/circulating angiogenic cells from patients with systemic lupus erythematosus are unable to 
diff  erentiate into mature endothelial cells in culture. Photomicrographs of primary blood mononuclear cells from a healthy control (left) and a 
patient with systemic lupus erythematosus (right) after 2 weeks of culture in proangiogenic media on fi  bronectin-coated plates. Cells were imaged 
via inverted phase microscopy at a total magnifi  cation of 100×. Photomicrographs by Seth G Thacker.
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Th  e inﬂ  ammatory cytokine TNF-α appears to play an 
important role in the initiation and perpetuation of 
atherosclerotic lesions in the general population. It 
increases the level of adhesion molecules on the surface 
of vascular endothelium and promotes enhanced levels of 
chemotactic proteins, which allows for recruitment of 
monocytes and T cells into the endothelial wall [44]. In 
SLE, serum TNF-α levels have been reported to be 
elevated and correlate with coronary calcium scores [26]. 
TNF-α levels are also increased in SLE patients with 
CVD compared to those without CVD, and this 
correlates with altered lipid proﬁ  les [45]. Additionally, it 
has been postulated that elevated levels of TNF-α may 
increase soluble VCAM-1 in SLE [46]. However, the 
exact role this cytokine plays in the development of 
vascular damage in SLE remains unclear.
IFN-γ, secreted by glycolipid-activated invariant natural 
killer T-cells, may also contribute to a pathogenic role in 
SLE-related atherosclerosis [47]. Th   e  anti athero genic 
cytokine transforming growth factor-β is decreased in SLE 
and this decrease may potentially play a role in related 
CVD [48]. Th  e cytokine IL-17, which stimulates produc-
tion of other pro-inﬂ   ammatory cytokines, as well as 
upregulation of chemokines and adhesion molecules, has 
been linked to atherosclerotic plaque development in non-
lupus-prone models. Atherosclerotic-prone mice have 
reduced plaque burden when transplanted with bone 
marrow deﬁ  cient in the IL-17 receptor [49]. SLE patients 
have elevated levels of IL-17 and Th   17 cells are expanded 
in SLE and can induce endothelial adhesion molecule 
upregulation [50,51]. Th  us, there is a theo  retical role for 
Th   17 T cells and IL-17 in the upregulation of inﬂ  ammatory 
mediators and adhesion molecules that contri  bute to CVD 
in SLE. Future studies should address if, indeed, any of 
these cytokines play a prominent role in vascular damage 
and atherosclerosis progression in this disease.
Adiponectin is an adipocytokine with potential bene-
ﬁ  cial  eﬀ   ects at sites of blood vessel injury through 
inhibition of monocyte adhesion to endothelial cells and 
of migration and proliferation of smooth muscle cells. 
However, this molecule is increased in lupus serum and 
independently correlates with augmented severity of 
carotid plaque, but not coronary calciﬁ  cation, in lupus 
patients [25,52]. One hypothesis to explain this dis-
crepancy is that chronic vascular damage in SLE leads to 
positive feedback on adiponectin-secreting cells. While 
this may lead to increases in levels of this cytokine, its 
eﬀ  ects are blunted at the site of endothelial damage due 
to the unique inﬂ  ammatory milieu in SLE [53]. Support-
ing a putative protective role for adiponectin in SLE-
mediated CVD, this molecule is required for the bene-
ﬁ  cial eﬀ  ects of rosiglitazone on atherosclerosis develop-
ment in a mouse model of SLE [54].
T cells
Th  1 CD4+ T cells play a pathogenic role in CVD and 
their diﬀ  erentiation is promoted in atherosclerotic lesions 
by the increased expression of IFN-γ and IL-12 [44]. 
Recent evidence suggests that these cells may also play a 
role in SLE-related CVD, as atherosclerosis-prone LDL 
receptor-deﬁ  cient mice have increased vascular inﬂ  am-
mation and CD4+ T cell inﬁ  ltration in their plaques after 
bone marrow transplant with lupus-susceptible cells [55]. 
As mentioned above, CD4+ T cells increase TRAIL 
expression when exposed to IFN-α, which can lead to 
plaque destabilization [41]. A hypothetical role for 
autoreactive CD4+ T cells in endothelial damage in SLE 
also exists. SLE autoreactive T cells can kill antigen 
presenting cells [56]. Endothelial cells have the ability to 
act as antigen presenting cells upon activation, and 
research on transplant rejection suggests that graft endo-
thelial cells are activated to a pro-inﬂ  ammatory pheno-
type and killed by host T cells during antigen presentation 
[57]. Further research into whether inter  actions between 
endothelial cells and SLE autoreactive T cells result in 
endothelial damage and an increased risk of athero-
sclerosis should be considered.
Th  e roles of other T-cell subsets in atherosclerosis 
develop  ment are being investigated. Invariant natural 
killer T cells, which recognize glycolipids and increase 
with the duration of lupus, may be proatherogenic [47]. 
In addition, whether the abnormalities reported in 
T  regulatory cells in SLE contribute to atherosclerosis 
develop  ment is unknown [58]. A putative role is 
suggested by the observation that if regulatory T cell 
function is compromised in mouse models of athero-
sclerosis, CVD development is signiﬁ  cantly more pro-
nounced [59].
Complement and immune complexes
Inhibition of complement regulatory proteins increases 
atherosclerosis in mice and decreases in the membrane-
attack complex attenuate atherosclerotic plaque forma-
tion [60]. Complement activated by inﬂ  ammatory stimuli 
can interact with immune complexes (ICs), such as seen 
in SLE, and result in upregulation of endothelial adhesion 
molecules, including E-selectin and VCAM-1. Th  ese 
molecules may enhance neutrophil recruitment and 
endothelial damage [61]. High levels of oxidized LDL/β2 
glycoprotein 1 complexes and anti-complex IgG or IgM 
have been reported in SLE. As the titers of these 
complexes correlate with a number of CVD risk factors 
[62], it is possible that they could be proatherogenic. Th  e 
complement component C1q has anti-atherosclerotic 
eﬀ  ects by facilitating macrophage clearance of oxidized 
and acetylated LDL. As C1q deﬁ  ciency is linked to SLE 
predisposition, its absence may also have a potential role 
in SLE-mediated atherosclerosis [63]. A role for 
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proposed [64], but the exact role this phenomenon plays 
in premature vascular damage in SLE remains unclear. 
ICs may also potentially play a role in atherosclerosis 
development. IC formation in rabbits accelerates diet-
induced athero  sclerosis, and mice deﬁ   cient in IC 
receptors have limited atherosclerotic development [65].
Lupus-related dyslipidemias
SLE patients have disturbances in lipoprotein levels and 
their processing in the bloodstream. High density 
lipoprotein (HDL) is decreased, while LDL, very low 
density lipoprotein and triglyceride levels are increased. 
Th  ese alterations may be related to abnormal chylo-
micron processing secondary to low levels of lipoprotein 
lipase [66]. Additionally, SLE patients have higher levels 
of pro-inﬂ   ammatory HDL, which is unable to protect 
LDL from oxidation and promotes endothelial injury. 
Increased pro-inﬂ  ammatory HDL in SLE is associated 
with augmented atherosclerosis [67]. In addition, the 
lipid proﬁ  le of SLE patients may be more susceptible to 
environmental eﬀ   ects. Lupus-prone mice exposed to 
high-fat chow showed increased pro-inﬂ  ammatory HDL 
and lipid deposition in vessels when compared to non-
lupus mice [68]. A high fat diet administered to LDL 
receptor-deﬁ   cient mice, made susceptible to SLE via 
bone marrow transplantation, resulted in very elevated 
lipid levels and signiﬁ  cant increases in mortality when 
compared to similar mice fed regular chow [55]. Th  us, 
predisposition to SLE may increase sensitivity to lipid 
perturbations by diet and other exposures.
Oxidative stress
Endothelial damage and the initiation of the atherogenic 
cycle may be inﬂ  uenced by the redox environment. SLE 
patients have increased levels of reactive oxygen and 
nitrogen species and antibodies to resultant protein 
adducts, which correlate with disease activity and provide 
an environment for oxidation of lipoproteins and 
atherosclerosis development [69]. Homocysteine, a mole-
cule with the capacity to increase reactive oxygen species 
in the bloodstream, is also increased in SLE patients and 
correlates with carotid IMT and with coronary calciﬁ  -
cation [5,70,71]. Further, defense mecha  nisms against an 
altered redox environment are decreased in SLE. For 
example, paraoxonase, an enzyme with antioxidant 
activity that circulates attached to HDL and prevents 
LDL oxidation, is decreased in this disease. Th  is corre-
lates with the presence of antibodies to HDL and β2-
glycoprotein and with enhanced atherosclerosis risk [72].
Antiphospholipid antibodies
Th   e role of antiphospholipid (APL) antibodies in prema-
ture CVD remains a matter of debate. β2-glyco  protein I, 
abundantly found in vascular plaques, has been 
hypothesized to be protective against athero  sclerosis 
development. Antibodies against this molecule could, in 
theory, be detrimental to the vessel wall and promote 
activation of inﬂ   ammatory cascades by IC formation 
[73]. APL antibodies may increase the likelihood of 
abnormal ankle brachial index and anti-cardiolipin anti-
body titers correlate with carotid IMT [70,74]. However, 
a recent study examining ﬂ   ow-mediated dilation and 
EPC numbers in primary APL syndrome (APS) did not 
detect any diﬀ  erence in these early markers of CVD risk 
compared with age and gender matched healthy controls 
[75]. Th   is supports previous work in which the presence 
of APL antibodies did not correlate with endothelial 
dysfunction or carotid IMT in SLE [7,76]. Using cardiac 
MRI to ﬁ  nd evidence of subclinical ischemic disease, 26% 
of patients with APS had occult myocardial scarring 
compared to 11% of controls. Th  is study, however, 
enrolled patients with secondary APS from SLE (22% of 
their APS cohort) and it is unclear whether a signiﬁ  cant 
number of the patients with myocardial damage also had 
lupus [77]. Th  us, the role of APL antibodies in athero-
sclerosis development in SLE remains unclear. Never-
theless, because of the arterial thrombosis associated 
with APS itself, there remains a putative role for these 
antibodies in the triggering of unstable angina and acute 
coronary syndromes.
Other autoantibodies
Autoantibodies against regulatory proteins in the 
atherogenic cycle in SLE may potentially contribute to 
CVD. Antibodies to the anti-atherogenic HDL and one of 
its components, Apo A-1, are increased in SLE and rise 
with disease ﬂ   ares [78]. SLE patients have increased 
levels of anti-lipoprotein lipase antibodies. Th  ese also 
increase with disease activity and may contribute to 
increased levels of triglycerides [79]. Antibodies to endo-
thelial cells are common in SLE and have been proposed 
to mediate endothelial injury [80]; however, various 
groups have shown that these antibodies may not 
correlate with other markers of endothelial dysfunction 
[81]. Additionally, antibodies to oxidized LDL, lipo-
protein lipase, CRP and annexin V may have a putative 
role in CVD in SLE [82,83]. Antibodies to heat shock 
proteins enhance atherosclerotic development in various 
non-lupus models and are increased in SLE serum 
[84,85]. Whether this class of antibodies contributes 
speciﬁ  cally to SLE-related atherosclerosis is unknown.
Preventive measures for cardiovascular disease in 
SLE
Various studies indicate that early and appropriate 
treatment of immune dysregulation in SLE could be key 
to hampering CVD development and progression in SLE. 
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azathioprine or corticosteroids had greater progression 
of CVD than those treated with higher doses [5]. Further, 
aortic atherosclerosis risk is lower in SLE patients who 
have undergone treatment with cyclophosphamide when 
compared to SLE patients who have not received this 
medication [9]. Th  e role of corticosteroid treatment is 
complex and poorly understood, with potentially dual 
eﬀ  ects on CVD risk that may depend on dose and time of 
exposure [8].
While no studies have shown a reduced incidence of 
CVD in patients taking antimalarials, these drugs have 
positive eﬀ  ects on glucose tolerance, lipid proﬁ  les,  and 
thrombosis potential [86]. Studies using surrogate markers 
for CVD have provided mixed results. Anti  malarials were 
signiﬁ  cantly associated with decreased presence of carotid 
plaque in patients with SLE [87]. A correlation between 
lack of antimalarial use and increased vascular stiﬀ  ness in 
SLE patients has been demonstrated, but no association 
between their use and coronary calciﬁ  cation was found 
[88,89]. A cohort study suggested a clear survival beneﬁ  t in 
SLE patients taking antimalarials, but the mechanisms for 
this eﬀ   ect remain to be determined [90]. Because 
antimalarials can weakly inhibit IFN-α production through 
inhibition of IC formation and toll-like receptor-7 and -9 
signaling [91], modulation of IFN-α levels with a potential 
improvement in endothelial function and vascular repair 
may contri  bute to the survival beneﬁ  t. More research into 
the vascular eﬀ   ects of antimalarials is needed to 
understand their beneﬁ  ts and whether they have an impact 
on athero  sclerotic development.
Mycophenolate mofetil (MMF), an immunosuppressive 
medication commonly used in SLE, may be potentially 
beneﬁ  cial in atherosclerosis. MMF has a protective eﬀ  ect 
on the development of both transplant and diet-mediated 
atherosclerosis in animals and is also beneﬁ  cial  in 
preventing coronary pathology in cardiac transplant 
patients [92]. MMF decreases atherosclerotic plaque 
inﬂ   ammation in patients treated for 2 weeks prior to 
carotid endarterectomy [93]. Whether this drug has a 
CVD beneﬁ  t in SLE patients remains to be determined, 
and future studies will hopefully address this question.
Th   e role of novel biologics in CVD prevention in SLE 
remains unknown. Currently, studies targeting type I 
IFNs, IL-17 and the various anti-B cell therapies are 
underway in SLE and other diseases. Long-term follow-
up to assess atherosclerosis progression in these groups 
would be important to identify if favorable eﬀ  ects are 
identiﬁ  ed. Given the recent observation that impairment 
in IL-1 pathways in SLE may mediate abnormal vascular 
repair in this disease [32], a note of caution is added with 
regards to the use of anakinra and other anti-IL-1 
therapies, particularly in SLE, but also in other diseases 
where aberrant vasculogenesis is observed.
Other non-disease modifying medications may also 
have a beneﬁ  t in SLE-related CVD. SLE patients have a 
higher incidence of metabolic syndrome and insulin 
resistance, and this correlates with increases in 
homocysteine and high sensitivity CRP [94]. Treatment 
of insulin-resistant states may improve CVD proﬁ  les in 
SLE. Our group reported that treatment of SLE-prone 
mice with the peroxisome proliferator-activated receptor 
γ (PPAR-γ) agonist pioglitazone, which is used to treat 
type II diabetes in humans, resulted in improved insulin 
sensitivity, improved endothelial function and restored 
EPC diﬀ   erentiation [94]. Additionally, rosiglitazone, 
another PPAR-γ agonist, decreased aortic atherosclerosis 
in lupus- and atherosclerosis-prone Gld.apoeE-/- mice 
[54]. How this class of medications would beneﬁ  t CVD in 
SLE patients warrants additional studies.
Guidelines for CVD prevention in SLE remain nebu-
lous. Th  e latest European League Against Rheumatism 
(EULAR) recommendations suggest yearly monitoring of 
traditional and/or non-lupus-speciﬁ  c CVD risk factors, 
including smoking, activity level, oral contraceptive use, 
hormonal therapies and family history of CVD. Monitor-
ing of blood pressure, lipids and glucose is also recom-
mended [95]. One group has proposed treating SLE as a 
coronary heart disease equivalent, targeting recommen-
da  tions as suggested by the Adult Treatment Panel 
guidelines (ATPIII) [96]. However, whether these guide-
lines will be suﬃ     cient to abrogate CVD risk in SLE 
remains to be determined. Th   e use of statins in SLE has 
not been systematically or extensively studied, but they 
have been shown to improve endothelium-dependent 
ﬂ  ow-mediated dilation and possibly slow progression of 
carotid IMT in adult lupus as well as increase EPC 
numbers in other conditions, including diabetes mellitus 
[97-99]. While trending toward a protective eﬀ  ect for 
carotid IMT thickness in pediatric SLE, prophylactic 
statin use in children did not show a statistically signiﬁ  -
cant diﬀ   erence compared to placebo [100]. A murine 
lupus/atherosclerosis model displayed decreased athero-
sclerosis and amelioration of renal disease when treated 
with simvastatin [101]. Statins can also block IFN-α 
production in peripheral blood from healthy controls in 
response to exposure to SLE patients’ serum. Th  is  block-
ade occurs through inhibition of the Rho kinase, likely in 
plasmacytoid DCs [102]. Future research will hopefully 
clarify the role of statin use in SLE patients.
Finally, diet may be an important modiﬁ  able risk factor 
that can alter predisposition to atherosclerotic lesions. 
LDL receptor-deﬁ   cient mice that underwent bone 
marrow transplant with SLE-prone cells had increased 
sensitivity to dietary fat. A Western-style diet containing 
21% fat increased atherosclerotic lesions, pathogenic 
antibody formation and severity of renal disease when 
compared to mice fed a regular diet [55]. A diﬀ  erent 
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administered leptin had accelerated and increased 
proteinuria, suggesting an interplay between diet and 
lupus [68]. Certainly, some murine lupus models have 
decreased life spans when fed a high-fat diet [103]. Th  us, 
further understanding of the role of diet on immune 
modulation and CVD risk in SLE may be key in vascular 
damage prevention.
Conclusion
Th   e CVD risk in SLE patients stems from a combination 
of traditional risk factors and SLE-speciﬁ  c mechanisms 
that incorporate chronic inﬂ  ammation,  endothelial 
dysfunction, decreased vascular repair through a type I 
IFN eﬀ   ect, antibody formation and perturbed lipid 
homeo    stasis and redox environment (Figure 2). Con-
tinued research into the mechanisms of lupus-related 
CVD will hopefully provide eﬀ  ective tools and targets to 
improve their survival and overall quality of life. 
Additionally, it is crucial that future clinical trials in SLE 
include biomarkers of vascular damage, functional 
studies of vascular health and assessment of subclinical 
and clinical CVD as endpoints in their eﬃ   cacy analysis.
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